Critical Analysis: IDEAYA Biosciences (NASDAQ:IDYA) versus Bolt Biotherapeutics (NASDAQ:BOLT)

Bolt Biotherapeutics (NASDAQ:BOLT) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bolt Biotherapeutics and IDEAYA Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1	1	2	0	2.25
IDEAYA Biosciences	1	1	13	0	2.80

Bolt Biotherapeutics currently has a consensus price target of $14.50, suggesting a potential upside of 120.36%. IDEAYA Biosciences has a consensus price target of $51.09, suggesting a potential upside of 50.44%. Given Bolt Biotherapeutics’ higher probable upside, equities analysts plainly believe Bolt Biotherapeutics is more favorable than IDEAYA Biosciences.

Insider and Institutional Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Bolt Biotherapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, IDEAYA Biosciences has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500.

Profitability

This table compares Bolt Biotherapeutics and IDEAYA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Valuation & Earnings

This table compares Bolt Biotherapeutics and IDEAYA Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$4.70 million	2.70	-$33.38 million	($16.44)	-0.40
IDEAYA Biosciences	$218.71 million	13.64	-$113.70 million	($1.94)	-17.51

Bolt Biotherapeutics has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

IDEAYA Biosciences beats Bolt Biotherapeutics on 9 of the 14 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.